{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T05:58:26Z","timestamp":1781157506089,"version":"3.54.1"},"reference-count":25,"publisher":"MJS Publishing, Medical Journals Sweden AB","license":[{"start":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T00:00:00Z","timestamp":1781049600000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Acta Derm Venereol"],"abstract":"<jats:p>Nemolizumab with background topical therapy (corticosteroids\u00b1calcineurin inhibitors) significantly improved skin lesions, itch and sleep in two global phase 3 trials (ARCADIA 1&amp;2) in adolescents and adults with moderate-to-severe atopic dermatitis through week (W)16. Efficacy and safety of nemolizumab, combined with background topical therapy, were evaluated for an additional 32 weeks(W16\u2013W48) with a focus on maintained skin responses in clinical responders (patients achieving Investigator\u2019s Global Assessment [IGA] score of 0\/1 [clear\/almost clear] or \u226575% improvement in Eczema Area and Severity Index [EASI-75] at W16). At W16, clinical responders (N=507) to nemolizumab every 4 weeks (Q4W) were rerandomized (1 : 1 : 1) to receive nemolizumab 30 mg-Q4W\/-Q8W\/placebo (nemolizumab-withdrawal) subcutaneously with background topical therapy. At W48, 61.5% (strata-adjusted difference versusnemolizumab-withdrawal group [\u0394], 11.8% [95% CI 1.3\u201322.3]) and 76.3% (\u0394, 12.4% [95% CI 2.7\u2013 22.0]) of patients in nemolizumab-Q4W; 60.4% (\u0394, 10.7% [95% CI 0.3\u201321.0]) and 75.7% (\u0394, 11.8% [95% CI 2.1\u201321.5]) in nemolizumab-Q8W; and 49.7% and 63.9% in nemolizumab-withdrawal group maintained response rate for IGA success and EASI-75, respectively. The percentage of patients who experienced \u22651 adverse events were similar across the groups (range: 53.5%\u201358.3%). Up to W48, skin responses were maintained without notable differences in the safety profile of both nemolizumab dosing regimens.<\/jats:p>","DOI":"10.2340\/actadv.v106.adv-2025-0085","type":"journal-article","created":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T05:12:09Z","timestamp":1781154729000},"source":"Crossref","is-referenced-by-count":0,"title":["Efficacy and Safety of Nemolizumab at Week 48: Results from the Maintenance Phase of Two Global Phase 3 Pivotal Studies (ARCADIA 1&amp;2) in Patients with Moderate-to-Severe Atopic Dermatitis"],"prefix":"10.2340","volume":"106","author":[{"given":"Andreas","family":"Wollenberg","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan I.","family":"Silverberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Franz J.","family":"Legat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie","family":"Tauber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vivian T.","family":"Laquer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"April W.","family":"Armstrong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew E.","family":"Pink","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luigi","family":"Naldi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gra\u017cyna","family":"Pulka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacek","family":"Zdybski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Athanasios","family":"Tsianakas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jorge","family":"Diaz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Inese","family":"Svarca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Beecker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Galina","family":"Balakirski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sylvia","family":"Pauser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liliana","family":"Ulianov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Ryzhkova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Loup","family":"Machu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christophe","family":"Piketty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1183","published-online":{"date-parts":[[2026,6,10]]},"reference":[{"key":"158380","doi-asserted-by":"crossref","unstructured":"Wollenberg A, Barbarot S, Bieber T, Christen-Zaech S, Deleuran M, Fink-Wagner A, et al. Consensus-based European guidelines for treatment of atopic eczema (atopic dermatitis) in adults and children: part I. J Eur Acad Dermatol Venereol 2018; 32: 657\u2013682.","DOI":"10.1111\/jdv.14891"},{"key":"158381","doi-asserted-by":"crossref","unstructured":"Wollenberg A, Christen\u2010Z\u00e4ch S, Taieb A, Paul C, Thyssen JP, de Bruin\u2010Weller M, et al. ETFAD\/EADV Eczema task force 2020 position paper on diagnosis and treatment of atopic dermatitis in adults and children. Acad Dermatol Venereol 2020; 34: 2717\u20132744.","DOI":"10.1111\/jdv.16892"},{"key":"158382","doi-asserted-by":"crossref","unstructured":"Silverberg JI, Gelfand JM, Margolis DJ, Boguniewicz M, Fonacier L, Grayson MH, et al. Patient burden and quality of life in atopic dermatitis in US adults: a population-based cross-sectional study. Ann Allergy Asthma Immunol 2018; 121: 340\u2013347.","DOI":"10.1016\/j.anai.2018.07.006"},{"key":"158383","doi-asserted-by":"crossref","unstructured":"Silverberg JI, Mohawk JA, Cirulli J, Nograles K, Punzalan JC, Kelly KM, et al. Burden of disease and unmet needs in atopic dermatitis: results from a patient survey. Dermatitis\u00ae 2023; 34: 135\u2013144.","DOI":"10.1089\/derm.2022.29015.jsi"},{"key":"158384","doi-asserted-by":"crossref","unstructured":"Silverberg JI, Pinter A, Alavi A, Lynde C, Bouaziz JD, Wollenberg A, et al. Nemolizumab is associated with a rapid improvement in atopic dermatitis signs and symptoms: subpopulation (EASI \u2265 16) analysis of randomized phase 2B study. J Eur Acad Dermatol Venereol 2021; 35: 1562\u20131568.","DOI":"10.1111\/jdv.17218"},{"key":"158385","doi-asserted-by":"crossref","unstructured":"Yu SH, Attarian H, Zee P, Silverberg JI. Burden of sleep and fatigue in US adults with atopic dermatitis. Dermatitis 2016; 27: 50\u201358.","DOI":"10.1097\/DER.0000000000000161"},{"key":"158386","doi-asserted-by":"crossref","unstructured":"Ruzicka T, Hanifin JM, Furue M, Pulka G, Mlynarczyk I, Wollenberg A, et al. Anti\u2013interleukin-31 receptor A antibody for atopic dermatitis. N Engl J Med 2017; 376: 826\u2013835.","DOI":"10.1056\/NEJMoa1606490"},{"key":"158387","doi-asserted-by":"crossref","unstructured":"Schneider S, Li L, Zink A. The new era of biologics in atopic dermatitis: a review. Dermatol Pract Concept 2021; 11: e2021144.","DOI":"10.5826\/dpc.1104a144"},{"key":"158388","doi-asserted-by":"crossref","unstructured":"Tampa M, Mitran CI, Mitran MI, Georgescu SR. A new horizon for atopic dermatitis treatments: JAK inhibitors. J Pers Med 2023; 13: 384.","DOI":"10.3390\/jpm13030384"},{"key":"158389","doi-asserted-by":"crossref","unstructured":"Radi G, Simonetti O, Rizzetto G, Diotallevi F, Molinelli E, Offidani A. Baricitinib: the first JAK inhibitor approved in europe for the treatment of moderate to severe atopic dermatitis in adult patients. Health Care (Don Mills) 2021; 9: 1575.","DOI":"10.3390\/healthcare9111575"},{"key":"158390","doi-asserted-by":"crossref","unstructured":"M\u00fcller S, Maintz L, Bieber T. Treatment of atopic dermatitis: recently approved drugs and advanced clinical development programs. Allergy 2024; 79: 1501\u20131515.","DOI":"10.1111\/all.16009"},{"key":"158391","doi-asserted-by":"crossref","unstructured":"Wollenberg A, Barbarot S, Bieber T, Christen-Zaech S, Deleuran M, Fink-Wagner A, et al. Consensus-based European guidelines for treatment of atopic eczema (atopic dermatitis) in adults and children: part II. J Eur Acad Dermatol Venereol 2018; 32: 850\u2013878.","DOI":"10.1111\/jdv.14888"},{"key":"158392","doi-asserted-by":"crossref","unstructured":"Datsi A, Steinhoff M, Ahmad F, Alam M, Buddenkotte J. Interleukin-31: the \u201citchy\u201d cytokine in inflammation and therapy. Allergy 2021; 76: 2982\u20132997.","DOI":"10.1111\/all.14791"},{"key":"158393","doi-asserted-by":"crossref","unstructured":"Kato A, Fujii E, Watanabe T, Takashima Y, Matsushita H, Furuhashi T, et al. Distribution of IL-31 and its receptor expressing cells in skin of atopic dermatitis. J Dermatol Sci 2014; 74: 229\u2013235.","DOI":"10.1016\/j.jdermsci.2014.02.009"},{"key":"158394","doi-asserted-by":"crossref","unstructured":"Orfali RL, Aoki V. Blockage of the IL-31 pathway as a potential target therapy for atopic dermatitis. Pharmaceutics 2023; 15: 577.","DOI":"10.3390\/pharmaceutics15020577"},{"key":"158395","doi-asserted-by":"crossref","unstructured":"Kabashima K, Matsumura T, Komazaki H, Kawashima M, Nemolizumab JP01 andJP02 Study Group. Nemolizumab plus topical agents in patients with atopic dermatitis (AD) and moderate-to-severe pruritus provide improvement in pruritus and signs of AD for up to 68 weeks: results from two phase III, long-term studies. Br J Dermatol 2022; 186: 642\u2013651.","DOI":"10.1111\/bjd.20873"},{"key":"158396","doi-asserted-by":"crossref","unstructured":"Kwatra SG, Yosipovitch G, Legat FJ, Reich A, Paul C, Simon D, et al. Phase 3 trial of nemolizumab in patients with prurigo nodularis. N Engl J Med 2023; 389: 1579\u20131589.","DOI":"10.1056\/NEJMoa2301333"},{"key":"158397","unstructured":"NEMLUVIO (nemolizumab-ilto) for subcutaneous injection [prescribing information online]. In: IUSA, editor. 2024."},{"key":"158398","unstructured":"Nemluvio: EPAR \u2013 Product information. In: European Medicines Agency, editor. Nemluvio, INN-nemolizumab; 2025."},{"key":"158399","doi-asserted-by":"crossref","unstructured":"Silverberg JI, Wollenberg A, Reich A, Tha\u00e7i D, Legat FJ, Papp KA, et al. Nemolizumab with concomitant topical therapy in adolescents and adults with moderate-to-severe atopic dermatitis (ARCADIA 1 and ARCADIA 2): results from two replicate, double-blind, randomised controlled phase 3 trials. Lancet 2024; 404: 445\u2013460.","DOI":"10.1016\/S0140-6736(24)01203-0"},{"key":"158400","doi-asserted-by":"crossref","unstructured":"Davis DMR, Drucker AM, Alikhan A, Bercovitch L, Cohen DE, Darr JM, et al. Guidelines of care for the management of atopic dermatitis in adults with phototherapy and systemic therapies. J Am Acad Dermatol 2024; 90: e43\u2013e56.","DOI":"10.1016\/j.jaad.2023.08.102"},{"key":"158401","doi-asserted-by":"crossref","unstructured":"Blauvelt A, Thyssen JP, Guttman-Yassky E, Bieber T, Serra-Baldrich E, Simpson E, et al. Efficacy and safety of lebrikizumab in moderate-to-severe atopic dermatitis: 52-week results of two randomized double-blinded placebo-controlled phase III trials. Br J Dermatol 2023; 188: 740\u2013748.","DOI":"10.1093\/bjd\/ljad022"},{"key":"158402","doi-asserted-by":"crossref","unstructured":"Silverberg JI, Adam DN, Zirwas M, Kalia S, Gutermuth J, Pinter A, et al. Tralokinumab plus topical corticosteroids as needed provides progressive and sustained efficacy in adults with moderate-to-severe atopic dermatitis over a 32-week period: an ECZTRA 3 post hoc analysis. Am J Clin Dermatol 2022; 23: 547\u2013559.","DOI":"10.1007\/s40257-022-00702-2"},{"key":"158403","doi-asserted-by":"crossref","unstructured":"Cork MJ, Eckert L, Simpson EL, Armstrong A, Barbarot S, Puig L, et al. Dupilumab improves patient-reported symptoms of atopic dermatitis, symptoms of anxiety and depression, and health-related quality of life in moderate-to-severe atopic dermatitis: analysis of pooled data from the randomized trials SOLO 1 and SOLO 2. J Dermatolog Treat 2020; 31: 606\u2013614.","DOI":"10.1080\/09546634.2019.1612836"},{"key":"158404","doi-asserted-by":"crossref","unstructured":"Bender BG, Ballard R, Canono B, Murphy JR, Leung DYM. Disease severity, scratching, and sleep quality in patients with atopic dermatitis. J Am Acad Dermatol 2008; 58: 415\u2013420.","DOI":"10.1016\/j.jaad.2007.10.010"}],"container-title":["Acta Dermato-Venereologica"],"original-title":[],"link":[{"URL":"https:\/\/medicaljournalssweden.se\/actadv\/article\/download\/46304\/54314","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/medicaljournalssweden.se\/actadv\/article\/download\/46304\/54316","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/medicaljournalssweden.se\/actadv\/article\/download\/46304\/54317","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/medicaljournalssweden.se\/actadv\/article\/download\/46304\/54314","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T05:12:18Z","timestamp":1781154738000},"score":1,"resource":{"primary":{"URL":"https:\/\/medicaljournalssweden.se\/actadv\/article\/view\/46304"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,10]]},"references-count":25,"URL":"https:\/\/doi.org\/10.2340\/actadv.v106.adv-2025-0085","relation":{},"ISSN":["1651-2057","0001-5555"],"issn-type":[{"value":"1651-2057","type":"electronic"},{"value":"0001-5555","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6,10]]}}}